A one-year trial of tiotropium Respimat plus usual therapy in COPD patients.
about
Tiotropium versus placebo for chronic obstructive pulmonary diseaseLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisTiotropium versus placebo for chronic obstructive pulmonary diseaseMortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trialsHealth-related quality of life measurement in asthma and chronic obstructive pulmonary disease: review of the 2009-2014 literatureComorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary diseasePharmacological strategies to reduce exacerbation risk in COPD: a narrative reviewThe association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysisTiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.Long-acting bronchodilator use after hospitalization for COPD: an observational study of health insurance claims dataCardiac safety of tiotropium in patients with COPD: a combined analysis of Holter-ECG data from four randomised clinical trials.Evidence synthesis for count distributions based on heterogeneous and incomplete aggregated data.Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary diseaseClinical effectiveness of the Respimat inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devicesQuestionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switchTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study.The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis.Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis.A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD.Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial.The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationaleComparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis.Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy.Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by ageEfficiency of Ipratropium Bromide and Albuterol Deposition in the Lung Delivered via a Soft Mist Inhaler or Chlorofluorocarbon Metered-Dose Inhaler.Budesonide and formoterol in a single pressurized metered-dose inhaler for treatment of COPD.Inhaled chemotherapy in lung cancer: future concept of nanomedicine.Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease.Tiotropium Respimat(®) Soft Mist™ inhaler: a review of its use in chronic obstructive pulmonary disease.Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression.TIOtropium Safety and Performance In Respimat (TIOSPIR): Analysis of Asian cohort of COPD patients.Long-acting muscarinic antagonists.The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease.Relationship Between FEV1 and Patient-Reported Outcomes Changes: Results of a Meta-Analysis of Randomized Trials in Stable COPD.Positioning of Long-Acting Muscarinic Antagonists in the Management of Asthma.Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis.Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies.
P2860
Q24194833-2AFE8657-20A9-4D7F-BDA6-1B09EC81D5E2Q24197853-DB38616D-7796-4082-905C-1B435729D556Q24202175-D7B20A30-F643-460E-BC90-03E4B5A84616Q24613889-2B2328D7-0B39-4FF5-BBC6-7F027D9D12C4Q26765780-CE1CF962-4BD3-4988-AFF2-AB2D38D665A0Q26823339-C7D71423-D97A-4584-89E6-C426AF02FA04Q28070274-FDA7A738-1C6A-48A9-8213-FE8CC8120F9FQ28070325-C5483241-1269-4D97-B3FC-E899347C6FA5Q30620671-9D6C4915-EE2B-4366-A1DE-DC58182F22B3Q30822043-F0EB6D3E-9F37-4904-B025-C0BEF019D034Q30877371-43D12C38-5C0D-4AA4-9E48-9CC38F793633Q30949429-5E8C93F8-F0E8-406D-8F0B-06323C191567Q34677811-A30D3AC3-C1E0-4378-8721-923278986FA7Q34721292-4F3BACE3-E8DF-450B-A941-38DCB225FBE4Q34944616-80FA41F8-F261-44D9-840C-49958A5044ADQ35344118-2F276258-B955-4E23-A1AB-A71B5A1A1A53Q35675649-0F1CFCD5-C78B-46C0-9855-F45C62AFDD44Q35774959-5C54FB53-928E-4848-B947-9E504CCE1295Q35802628-135A0000-9200-4661-BA4F-F52F3B7885E2Q35838660-ADD1B748-F8F1-49A9-9EA6-C5CCDF91A7BAQ35999260-09E1C874-5F67-4165-8227-7EE802ED7B77Q36251424-D759C1E1-9829-42F2-87D0-AE64C3E32FFCQ36557670-AF8A9F87-0227-4305-A946-2302B36C4CBDQ36752114-C2475D65-FFE4-4753-8C9A-A640A66F7DE6Q37170227-59149008-5A8A-4CF4-A01A-DF2D426F97ADQ37278903-B2F35A1B-D32D-4DD3-A68C-86955BB483D8Q37397852-15283185-83D5-45A5-A028-0EF6DE827C9DQ37701125-F8C8133B-114E-4E84-8F42-0A99C70823B9Q37815483-E28B633A-A176-43DB-BAFA-7E9D6761B6CDQ38012447-3140C044-968A-4C14-BA32-6F96621BEB5AQ38112092-A8B43E62-39BC-4AD2-8E35-206E94E67A3DQ38258538-ED93EA64-E832-4EE4-B569-9ECB0CC42B8CQ38317463-CBB0F254-3139-495C-82A4-94B9F6FA7EE0Q38411864-CA9D7211-1C55-4C77-B806-CDD5D454DD8BQ38537326-53E3305F-30EA-43D4-8FFA-F6BEA529C7BBQ38592062-D89EA4D7-8851-4DD6-BF33-7B30883CB014Q38604644-42F89373-D3F3-4B10-9B06-DF5849109424Q38662759-F003028E-28C0-4FCA-A511-590CB6A87120Q38690660-4592F94E-5A58-46A4-9B14-6FA84C5FE6E5Q38982942-D0BB6450-B309-43DF-8E9A-FB9ACE0F94FA
P2860
A one-year trial of tiotropium Respimat plus usual therapy in COPD patients.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
A one-year trial of tiotropium Respimat plus usual therapy in COPD patients.
@en
A one-year trial of tiotropium Respimat plus usual therapy in COPD patients.
@nl
type
label
A one-year trial of tiotropium Respimat plus usual therapy in COPD patients.
@en
A one-year trial of tiotropium Respimat plus usual therapy in COPD patients.
@nl
prefLabel
A one-year trial of tiotropium Respimat plus usual therapy in COPD patients.
@en
A one-year trial of tiotropium Respimat plus usual therapy in COPD patients.
@nl
P2093
P1433
P1476
A one-year trial of tiotropium Respimat plus usual therapy in COPD patients.
@en
P2093
E D Bateman
N Siafakas
P304
P356
10.1016/J.RMED.2010.06.004
P577
2010-10-01T00:00:00Z